Active	Status	Sponsor type	Region	Phase	Filter
5 Active 3 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Pinter-Brown, Lauren C
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022 Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022 Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021 Jun 2021 - Jun 2021: Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021 Preliminary data from cohort 2 of TELLOMAK trial for mycosis fungoides Jun 2021 - Jun 2021: Preliminary data from cohort 2 of TELLOMAK trial for mycosis fungoides First patient in trial for PTCL Sep 2019 - Sep 2019: First patient in trial for PTCL Enrollment of first patient in TELLOMAK trials for Sezary syndrome May 2019 - May 2019: Enrollment of first patient in TELLOMAK trials for Sezary syndrome More	Active, not recruiting	2	170	Europe, US	IPH4102, lacutamab	Innate Pharma	Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome	10/23	01/26
LuminICE-203, NCT05883449: Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL	Recruiting	2	154	US	AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2	Affimed GmbH, Artiva Biotherapeutics, Inc.	Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma	04/26	11/27
NCT00091208: CpG 7909 in Treating Patients With Cutaneous T-Cell Lymphoma	Active, not recruiting	1/2		US	agatolimod sodium	Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)	Lymphoma
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Recruiting	1/2	108	US	AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine	Artiva Biotherapeutics, Inc.	Non Hodgkin Lymphoma	11/24	11/24
NCT05321147: Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2	Completed	1	20	US, RoW	lacutamab, IPH4102	Innate Pharma	Peripheral T Cell Lymphoma	11/23	02/24